Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine
Vingerhoets et al.: A European observational study in antiretroviral treatment-experienced HIV-1 infected patients explored the efficacy of etravirine (ETR) plus darunavir/ritonavir (DRV/r) versus ETR plus an alternative boosted protease inhibitor (PI) together with an optimized background regimen. Overall, there was no difference in virological response rates between the two groups, for a given set of measured confounding factors. These data suggest that ETR exhibits similar efficacy together with a PI other than DRV/r, combined with an optimized background regimen. However, the results must be interpreted with caution given the small sample size.